Related Experiment Videos
Anti-TNF-alpha-induced systemic lupus syndrome
M Debandt1, O Vittecoq, V Descamps
1Rheumatology Department, Georges Pompidou Teaching Hospital, 20 rue Leblanc, 75015 Paris, France. debandt@club-internet.fr
Clinical Rheumatology
|February 28, 2003
Summary
TNF-alpha inhibitors can induce autoimmune disorders like lupus in rheumatoid arthritis patients. This study details new cases of infliximab- and etanercept-induced lupus, highlighting the need for vigilance.
Area of Science:
- Immunology
- Rheumatology
Background:
- Anti-tumor necrosis factor-alpha (TNF-alpha) therapies offer promising treatment for rheumatoid arthritis (RA).
- Despite clinical efficacy, concerns exist regarding drug-induced autoimmune disorders.
Observation:
- Some patients on TNF-alpha inhibitors develop antinuclear (ANA) and anti-DNA antibodies.
- Few cases of lupus erythematosus induced by TNF blockers have been reported, primarily with infliximab.
Findings:
- This report details one new case of infliximab-induced lupus syndrome.
- Two new cases of etanercept-induced lupus syndrome are also presented.
- All three patients had rheumatoid arthritis and prior isolated positive ANA.
Implications:
- These findings underscore the potential for TNF blockers to induce lupus syndromes.
- Careful monitoring for autoimmune disorders in RA patients receiving anti-TNF therapy is crucial.
- Further research into the mechanisms and management of drug-induced lupus is warranted.